FDA approves Genentech’s sNDA for influenza therapy in children
Xofluza is indicated to treat acute uncomplicated influenza in healthy children aged five to less than 12 years with symptoms for not over 48 hours. The regulatory approval
Diamyd Medical has announced the receipt of fast track designation from the US Food and Drug Administration (FDA) for type 1 diabetes treatment, Diamyd.
The new fully synthetic fluorocycline intravenous antibiotic, xerava has been developed to use as a first-line empiric monotherapy to treat multidrug resistance (MDR) infections, such as MDR Gram-negative
Under the collaboration, the company will partner with the MD Anderson scientists on preclinical trials for further validating TransCode’s RNA-targeted oncology therapy and diagnostic candidates. They will also